Clinical Trial Update: A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AZD2693 in carriers of the PNPLA3 148M risk allele with non-cirrhotic nonalcoholic steatohepatitis with fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• AZD2693

Snippet

Sponsor: AstraZeneca | Conditions: Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED